Overall, SSRIs provided high benefit (remission) with low risk of adverse events. Across individual SSRIs, sertraline and escitalopram were identified as the most efficacious agents with low risk of adverse events.

The treatment of panic disorder and acute panic anxiety in 2026 continues to rely on two primary classes of medication: Selective Serotonin Reuptake Inhibitors (SSRIs) and Benzodiazepines. For long-term management and the prevention of future attacks, SSRIs like Sertraline (Zoloft) or Escitalopram (Lexapro) are generally considered the "gold standard" because they address the underlying chemical imbalance with a lower risk of dependency. For "as-needed" or immediate relief of a severe panic attack, Benzodiazepines such as Alprazolam (Xanax) or Lorazepam (Ativan) are highly effective because they work rapidly to calm the central nervous system. However, these are typically prescribed for short-term use due to the risk of tolerance and addiction. In 2026, newer treatments like Fasedienol (a nasal spray) are emerging in clinical guidelines as fast-acting, non-systemic alternatives for "on-demand" relief. It is crucial to consult with a psychiatrist or medical professional to determine the best course of action, as the "best" drug depends on an individual's medical history, the frequency of attacks, and whether the goal is immediate rescue or long-term stabilization.